Friday, 16 October 2026European Markets

ERAMET And EXPLOSIFS PROD.CHI Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(vianews) - eramet (era.pa) is among this list of stock assets with the highest dividend rate and return on equity on the basic materials sector.

financial asset price forward dividend yield return on equity
eramet (era.pa) €70.45 1.53% 0.57%
explosifs prod.chi (expl.pa) €147.00 0.74% 16.87%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. eramet (era.pa)

1.53% forward dividend yield and 0.57% return on equity

eramet s.a. operates as a mining and metallurgical company in france, asia, europe, north america, and internationally. the company extracts and processes manganese ore and nickel ore; and extracts and develops mineral sands. it also produces ferronickel, nickel pig iron, briquettes, nickel salts, high purity nickel, nickel ferroalloys, and alloy steel and casting; manganese alloys, such as high-carbon ferromanganese, silicomanganese, low and medium-carbon ferromanganese, and low-carbon silicomanganese for use in batteries, pigments, construction, and automotive industries; and mineral sands, such as titanium dioxide, high-purity pig iron, zircon, and ilmenite used in ceramics and pigments. in addition, it operates moanda mine in gabon; nickel mines in new caledonia and indonesia; and mineral sand mine in senegal and argentina. eramet s.a. was incorporated in 1880 and is headquartered in paris, france.

earnings per share

as for profitability, eramet has a trailing twelve months eps of €3.58.

pe ratio

eramet has a trailing twelve months price to earnings ratio of 19.68. meaning, the purchaser of the share is investing €19.68 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.57%.

revenue growth

year-on-year quarterly revenue growth declined by 30.9%, now sitting on 3.34b for the twelve trailing months.

yearly top and bottom value

eramet's stock is valued at €70.45 at 02:30 est, way under its 52-week high of €114.50 and way above its 52-week low of €57.85.

more news about eramet.

2. explosifs prod.chi (expl.pa)

0.74% forward dividend yield and 16.87% return on equity

epc groupe engages in the manufacture, storage, and distribution of explosives in europe, africa, asia pacific, and the americas. the company also provides drilling and mining services; logistics services; and demolition services, including mechanical demolition, deconstruction and blasting of buildings, waste management, and asbestos removal. in addition, it produces 2-ethylhexyl nitrate, a diesel fuel additive that reduces emissions and enhances diesel engine performance. it serves customers operating in the mining, cement, aggregates, civil engineering, and defense industries. epc groupe was founded in 1893 and is headquartered in paris, france. epc groupe operates as a subsidiary of ste e.j. barbier.

earnings per share

as for profitability, explosifs prod.chi has a trailing twelve months eps of €8.63.

pe ratio

explosifs prod.chi has a trailing twelve months price to earnings ratio of 17.03. meaning, the purchaser of the share is investing €17.03 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.87%.

moving average

explosifs prod.chi's worth is higher than its 50-day moving average of €136.04 and way higher than its 200-day moving average of €119.30.

more news about explosifs prod.chi.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com